Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Finn, Richard S.; Dering, Judy; Ginther, Charles; Wilson, Cindy A.; Glaspy, Padraic; Tchekmedyian, Nishan; Slamon, Dennis J.
Breast Cancer Research & Treatment.
105(3):319-326, November 2007.
(Format: HTML, PDF)